Drug Profile
JTT 252
Alternative Names: JTT-252Latest Information Update: 06 Aug 2015
Price :
$50
*
At a glance
- Originator Akros Pharma
- Class Antihyperglycaemics
- Mechanism of Action Sodium-glucose transporter 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 04 Aug 2015 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (PO)
- 30 Apr 2015 Akros Pharama terminates a phase I trial in Diabetes mellitus in USA (PO) (NCT02120976)
- 01 Apr 2014 Phase-I clinical trials in Type-2 Diabetes mellitus in USA (PO) (NCT02120976)